Bioton S.A. (BIO) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.004x

Based on the latest financial reports, Bioton S.A. (BIO) has a cash flow conversion efficiency ratio of 0.004x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł2.49 Million ≈ $685.01K USD) by net assets (zł593.97 Million ≈ $163.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIO net asset quality score to measure how much of total assets are equity-financed.

Bioton S.A. - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how Bioton S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Bioton S.A.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.

Bioton S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bioton S.A. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Mercan Kimya Sanayi ve Ticaret AS
IS:MERCN
0.056x
Edel SE & Co. KGaA
F:EDL
0.113x
DHI Group Inc
NYSE:DHX
0.049x
Barington/Hilco Acquisition
NASDAQ:BHAC
-0.004x
CeoTronics AG
F:CEK
0.061x
AUGUSTA GOLD DL-0001
F:7RZ
N/A
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
0.279x
PT Mulia Industrindo Tbk
JK:MLIA
-0.004x

Annual Cash Flow Conversion Efficiency for Bioton S.A. (2005–2025)

The table below shows the annual cash flow conversion efficiency of Bioton S.A. from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see BIO market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 zł593.97 Million
≈ $163.47 Million
zł22.62 Million
≈ $6.23 Million
0.038x -38.10%
2024-12-31 zł590.55 Million
≈ $162.53 Million
zł36.33 Million
≈ $10.00 Million
0.062x -5.86%
2023-12-31 zł606.36 Million
≈ $166.88 Million
zł39.62 Million
≈ $10.91 Million
0.065x -29.38%
2022-12-31 zł606.06 Million
≈ $166.80 Million
zł56.08 Million
≈ $15.43 Million
0.093x +943.56%
2021-12-31 zł622.74 Million
≈ $171.39 Million
zł5.52 Million
≈ $1.52 Million
0.009x -86.90%
2020-12-31 zł619.64 Million
≈ $170.54 Million
zł41.95 Million
≈ $11.54 Million
0.068x -15.64%
2019-12-31 zł582.00 Million
≈ $160.17 Million
zł46.71 Million
≈ $12.85 Million
0.080x +105.18%
2018-12-31 zł712.79 Million
≈ $196.17 Million
zł27.88 Million
≈ $7.67 Million
0.039x +72.80%
2017-12-31 zł773.25 Million
≈ $212.81 Million
zł17.50 Million
≈ $4.82 Million
0.023x -20.41%
2016-12-31 zł813.83 Million
≈ $223.98 Million
zł23.15 Million
≈ $6.37 Million
0.028x -4.50%
2015-12-31 zł806.64 Million
≈ $222.00 Million
zł24.02 Million
≈ $6.61 Million
0.030x +2.81%
2014-12-31 zł1.45 Billion
≈ $397.84 Million
zł41.87 Million
≈ $11.52 Million
0.029x -49.82%
2013-12-31 zł1.39 Billion
≈ $381.20 Million
zł79.96 Million
≈ $22.01 Million
0.058x -46.71%
2012-12-31 zł1.34 Billion
≈ $367.86 Million
zł144.80 Million
≈ $39.85 Million
0.108x +775.77%
2011-12-31 zł1.38 Billion
≈ $381.14 Million
zł-22.20 Million
≈ $-6.11 Million
-0.016x -169.02%
2010-12-31 zł1.17 Billion
≈ $321.97 Million
zł27.17 Million
≈ $7.48 Million
0.023x +131.27%
2009-12-31 zł1.08 Billion
≈ $297.22 Million
zł-80.22 Million
≈ $-22.08 Million
-0.074x -343.58%
2008-12-31 zł1.24 Billion
≈ $340.63 Million
zł37.74 Million
≈ $10.39 Million
0.030x +5202.64%
2007-12-31 zł886.79 Million
≈ $244.06 Million
zł-530.00K
≈ $-145.86K
-0.001x +95.51%
2006-12-31 zł808.11 Million
≈ $222.40 Million
zł-10.76 Million
≈ $-2.96 Million
-0.013x -147.73%
2005-12-31 zł255.42 Million
≈ $70.29 Million
zł7.13 Million
≈ $1.96 Million
0.028x --

About Bioton S.A.

WAR:BIO Poland Biotechnology
Market Cap
$90.03 Million
zł327.14 Million PLN
Market Cap Rank
#19499 Global
#157 in Poland
Share Price
zł3.81
Change (1 day)
-0.52%
52-Week Range
zł3.74 - zł4.55
All Time High
zł15.39
About

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes m… Read more